Literature DB >> 15172890

Elastic properties of the respiratory system in infants with cystic fibrosis.

Robert S Tepper1, Andrea Weist, Tamica Williams-Nkomo, Jeffrey Kisling.   

Abstract

Respiratory system compliance (Crs) in infants with cystic fibrosis (CF) has been reported as decreased or not different compared with healthy control subjects; however, the reported measurements of Crs were "quasi-static" or by the single-breath occlusion technique, with all measurements limited to tidal lung volume, as well as using inspiratory rather than expiratory pressures. We compared the passive elastic properties of the respiratory system of sleeping infants with CF (n = 10) and healthy control subjects (n = 34) by measuring static deflation pressure--volume (PV) curves from a lung volume at 30 cm H(2)O (V(30)) to FRC. There was no significant difference between the groups for Crs, which was measured as the slope between airway relaxation pressures of 5 and 15 cm H(2)O, the linear portion of the deflation PV curve. In addition, when PV curves were normalized to V(30), there were no differences between the infants with CF and healthy control subjects in the fractional volumes at any airway pressure. The infants with CF had significantly lower forced expiratory flows; however, lower flows did not correlate with fractional volumes measured from the PV curve. Our findings indicate that infants with CF have normal elastic properties of the respiratory system.

Entities:  

Mesh:

Year:  2004        PMID: 15172890     DOI: 10.1164/rccm.200401-132OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  1 in total

1.  High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis.

Authors:  Tanya M Martínez; Conrado J Llapur; Tamica H Williams; Cathy Coates; Richard Gunderman; Mervyn D Cohen; Michelle S Howenstine; Osama Saba; Harvey O Coxson; Robert S Tepper
Journal:  Am J Respir Crit Care Med       Date:  2005-07-28       Impact factor: 21.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.